1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Sanofi’s Dupixent Has Greater Benefit In COPD Patients With Higher Type II Inflammation

Full Pivotal Data Suggests

 
• By Ayisha Sharma

The IL-4/IL-3 inhibitor attained a greater reduction in exacerbations in patients with a higher level of a biomarker for type 2 inflammation according to complete pivotal data, but questions remain on the timing of regulatory filings.  

Man in polluted city holding a face mask over his face
Air Pollution Is One Of The Causes of COPD • Source: Shutterstock

Sanofi and Regeneron Pharmaceuticals, Inc.’s inflammatory disease blockbuster Dupixent has shown enhanced efficacy in a subgroup of chronic obstructive pulmonary disease (COPD) patients according to full data from the closely-watched Phase III BOREAS trial, but observers are more concerned with timelines for regulatory filings.

Last year, revenues of the IL-4/IL-3 inhibitor Dupixent (dupilumab), which is approved in a range of inflammatory-driven conditions including atopic dermatitis and asthma, rocketed by 44% to €8.29bn ($8.95bn)

More from Clinical Trials

Lilly Builds Obesity Momentum With New SURMOUNT Data Besting Novo Nordisk

 
• By Alaric DeArment

The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.

Insilico Fast-Tracks First AI-Designed TNIK Inhibitor Into For IPF

 
• By Dexter Jie Yan

InSilico will leapfrog Phase IIb to progress its AI-generated candidate for idiopathic pulmonary fibrosis directly into a Phase III trial in China, as it prepares for an IPO in Hong Kong.

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.

More from R&D

CRISPR Therapeutics Unveils Promising Early In Vivo Cholesterol-Lowering Results

 
• By Andrew McConaghie

The Phase I results are the best to date among ANGPTL3-targeting candidates in the pipeline, but analysts will wait for further updates before predicting a likely winner.

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By Kevin Grogan

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’

Marea Eyes Cardioprotective Benefit With ANGPTL4 Inhibition

 
• By Joseph Haas

Phase IIa data for ANGPTL4-targeted antibody shows reduced triglycerides and remnant cholesterol, which Marea asserts indicates potential to protect against cardiovascular outcomes.